Background
According to the cancer stem cell (CSC) hypothesis [1, 2] , tumorigenicity, the capacity to propagate a tumor, is not an intrinsic property of any tumor cell, but the defi ning function of a specialized cell-type, the CSC. Within individual tumors, only CSCs are able to reform a tumor after transplantion in mouse recipients. Notably, these tumors have the same cellular heterogeneity as the initial one, including both tumorigenic (CSCs) and nontumorigenic cells (the remaining cells). CSCs express some surface markers of the corresponding normal tissue stem cells, while the non-tumorigenic remaining cells express markers of progenitors or more diff erentiated cells.
Th e existence of a cell hierarchy within tumors is shown by CSCs' ability to reform biologically heterogeneous tumors also from single-cell transplantation, whereby a CSC generates, through a single asymmetric mitotic division, phenocopies of itself (self-renewal) and diff erentiated/non-tumorigenic tumor cells [3] .
While the CSC theory lacks defi nitive proof, it bears important implications for cancer treatment. Anti-cancer drugs have been selected in early clinical trials for their property to reduce tumor size, an eff ect that refl ects their ability to kill the bulk of tumor cells, but not necessarily the rare CSCs. Th ese might then become the cellular base of clinical relapse.
Drugs capable of reducing tumor size and producing clinical remission are available for many tumor types. Nonetheless, tumors eventually relapse in a large pro portion of cases, even after long intervals. For instance, in mammary tumors relapse rate after chemotherapy and/ or radiotherapy remains very high (up to approximately 50%) and may occur as late as 30 years after manifestation of disease. Th us, the initial treatment might have spared a small population of cells with the ability to survive for long periods of time and to re-initiate tumor growth; cells that, according to the CSC theory, would be, by defi nition, CSCs. Stem cells are generally resistant to cytotoxic agents, probably because they are usually non-proli ferating cells. Are CSCs also chemo-and radio-resistant, thus surviving in vivo treatments and initiating tumor regrowth? If so, increasing CSC sensitivity to the available chemo/radiotherapy treatments becomes a priority.
Article
Th e work published by Atkinson and colleagues [4] demonstrates, in preclinical models of mammary tumors, that CSCs are, in fact, resistant to radiotherapy, and that their sensitivity dramatically increases with concomitant local hyperthermia.
Th erapeutic hyperthermia involves heating tissues to temperatures around 41 to 45°C. While its potential benefi ts in cancer treatment were already acknowledged 5,000 years ago [5] , results from recent clinical trials are often controversial, perhaps because of inadequate delivery systems, lack of appropriate monitoring of the temperature reached by the tumor, or intrinsic limitations of conventional heating sources. Notably, a meta-analysis of more recent data from randomized clinical trials of breast cancer patients, supported by thorough thermometry documentation, demonstrated that hyperthermia improves signifi cantly both local tumor control and survival after radiation therapy [6] , suggesting that, if properly delivered, it is a potent radiation sensitizer. 
Abstract
Tumour relapse is believed to be caused by rare cancer-cells with stem-cell properties (cancer stem cells) that are intrinsically resistant to available treatments. The identifi cation of novel strategies to increase their sensitivity has major clinical implications. Latest clinical trials have shown a positive antitumoral eff ect of hyperthermia in combination with chemotherapy or radiotherapy. In a recent paper, the combination of increased temperature at the tumour site, generated by laser treatment of intravenouslyinjected gold nanoshells, and ionizing radiations enhances radiosensitivity of cancer stem cells and tumor response. At the root of the success of hyperthermia in enhancing radio-sensitization of cancer stem cells is the inhibition of their capacity to repair DNA damage, aff ecting the survival rate of these cells.
Atkinson and colleagues used an innovative protocol of therapeutic hyperthermia based on the use of silica core nanoshells associated with thermocouple measurements. Nanoparticles are known to passively concentrate in tumor tissues after intravenous injection, thus allowing enhanced delivery of anticancer agents to malignant cells. Th ose employed in this study were designed to absorb light in the near-infrared spectrum and then release energy in the form of heat, signifi cantly increasing the intra-tumoral temperature.
Th e authors used two preclinical model systems of breast cancer: the mouse p53-null mammary tumor, obtained after transplantation of p53-null mammary cells, and xenotransplants of 'triple-negative' human mammary tumors. Tumor-bearing mice were treated with radiotherapy alone (single dose) or radiotherapy plus hyperther mia (concurrently). Local hyperthermia was induced by near-infrared illumination of the tumor 24 hours after intravenous injection of the nanoparticles, leading to an intra-tumoral temperature of 42°C within 5 minutes, which persisted for 20 minutes. Mice were sacrifi ced 2 to 3 days after treatment and tumors analyzed for their CSC content, both directly within the tumor (using markers to identify CSC-enriched populations) and indirectly by their ability to form spheroids in culture or tumors in recipient mice upon limiting-dilution transplantation.
Viewpoint
Th e diff erent treatment modalities gave comparable results in both model systems. Radiotherapy alone induced an overall decrease in tumor size, although to varying degrees. However, regardless of the degree of volume reduction, radiotherapy alone increased the relative numbers of CSCs (from 30 to 150%). Notably, tumors that re-formed after X-ray treatment (upon transplantation) were more undiff erentiated tumors. Hyperthermia alone did not show signifi cant eff ects on tumor size or frequency of CSCs. Th e combination of X-rays plus hyperthermia, however, caused a greater regression of tumor size than the ionizing-radiation treatment alone, and, remarkably, a signifi cantly lower percentage of CSCs. Accordingly, after the combination treatment, re-growing tumors appeared more diff erentiated.
Th us, CSCs are resistant to X-rays and are selected during treatment in vivo. Th ese results indirectly suggest that resistant CSCs are responsible for tumor re-growth after-treatment, or, at least, that the re-formed tumors tend to lose their most diff erentiated component. Th ey also show that hyperthermia, although ineff ective by itself, increases the eff ect of X-rays on tumor growth by increasing CSC sensitivity to them.
Th is study also provides insights into the molecular mechanisms underlying the sensitizing eff ect of hyperthermia. Th e cytotoxic eff ect of X-rays is mainly due to induction of DNA double-strand breaks. While it was already known that CSCs are resistant to X-rays due to their unique ability to repair DNA damage, the authors show that hyperthermia diminishes this ability. It is likely, therefore, that, in the presence of hyperthermia, X-rays induce excess DNA damage and CSC death. It was recently shown that inactivation of DNA repair pathways causes DNA-damage 'overloading' in leukemia stem cells [7] , leading to their functional exhaustion and preventing the development of the tumor clone. Th us, a growing body of evidence links CSC inherent resistance to DNA damage to tumorigenicity and to their resistance to currently available cytotoxic drugs. Th e identifi cation of treatment modalities, including hyperthermia, that counteract the intrinsic capacity of CSCs to survive DNA damage emerges as a new promising strategy to target tumor growth and prevent tumor relapse.
Abbreviations CSC, cancer stem cell.
